Table 1 Demographic and clinical characteristics of 149 patients with SMADCs, grouped by IASLC/ATS/ERS classification of dominant tumor (DT).
Group variables | Low-grade (lepidic; %) | Intermediate-grade (acinar, papillary; %) | High-grade (micropapillary, solid;%) | p value | |
|---|---|---|---|---|---|
Number | 149 (100%) | 32 (21.5) | 87 (58.4) | 30 (20.1) | |
Age (years old) | 62.0 ± 10.8 | 58.5 ± 9.6 | 62.1 ± 11.1 | 65.6 ± 10.3 | 0.033 |
Gender | 0.112 | ||||
Male | 54 | 7 (21.9) | 33 (37.9) | 14 (46.7) | |
Female | 95 | 25 (78.1) | 54 (62.1) | 16 (53.3) | |
Smoking status (yes) | 0.018 | ||||
Previously or currently | 41 | 5 (15.6) | 22 (25.3) | 14 (46.7) | |
Non-smoker | 108 | 27 (84.4) | 65 (74.7) | 16 (53.3) | |
Preoperative CEA level (ng/mL) | 0.030 | ||||
≥ 6.0 ng/mL | 22 | 3 (9.4) | 10 (11.5) | 9 (30.0) | |
< 6.0 | 127 | 29 (90.6) | 77 (88.5) | 21 (70.0) | |
Tumor size (cm) | 2.26 ± 1.34 | 1.29 ± 0.69 | 2.35 ± 1.27 | 3.01 ± 1.47 | < 0.001 |
Resected tumor number(s) | 2.4 ± 1.0(2–9) | 2.8 ± 1.2 | 2.6 ± 1.5 | 2.4 ± 1.0 | 0.436 |
Radiologic appearance of DT | < 0.001 | ||||
Pure GGO | 34 | 21 (65.6) | 13 (14.9) | 0 | |
GGO-dominant | 39 | 10 (31.3) | 26 (29.9) | 3 (10.0) | |
Solid-dominant | 76 | 1 (3.1) | 48 (55.2) | 27 (90.0) | |
Laterality | 0.172 | ||||
Ipsilateral | 111 | 27 (84.4) | 60 (69.0) | 24 (80.0) | |
Bilateral | 38 | 5 (15.6) | 27 (31.0) | 6 (20.0) | |
Tumor location | 0.800 | ||||
At different lobe | 100 | 20 (62.5) | 60 (69.0) | 20 (66.7) | |
At the same lobe | 49 | 12 (37.5) | 27 (31.0) | 10 (33.3) | |
TNM stage (AJCC 8th) | < 0.001 | ||||
pTis | 12 | 12 | 0 | 0 | |
pT1a | 15 | 5 | 9 | 1 | |
pT1b | 21 | 3 | 18 | 0 | |
pT1c | 14 | 4 | 9 | 1 | |
pT2a | 74 | 8 | 45 | 21 | |
pT2b | 8 | 0 | 5 | 3 | |
pT3 | 4 | 0 | 0 | 4 | |
pT4 | 1 | 0 | 1 | 0 | |
Pleural invasion | < 0.001 | ||||
P0 | 71 | 24 (75.0) | 41 (47.1) | 6 (20.0) | |
P1 + P2 + P3 | 78 | 8 (25.0) | 46 (52.9) | 24 (80.0) | |
Differentiation | < 0.001 | ||||
Well + moderate | 97 | 31 (96.9) | 61 (70.1) | 5 (16.7) | |
Poorly | 52 | 1 (3.1) | 26 (29.9) | 25 (83.3) | |
Lymphovascular invasion | < 0.001 | ||||
Nil | 119 | 32 (100) | 72 (82.8) | 15 (50.0) | |
Yes | 30 | 0 | 15 (17.2) | 15 (50.0) | |
Adjuvant chemotherapy | < 0.001 | ||||
Nil | 96 | 31 (96.9) | 55 (63.2) | 10 (33.3) | |
Yes | 53 | 1 (3.1) | 32 (36.8) | 20 (66.7) | |
2nd dominant tumor | < 0.001 | ||||
Non-invasive (lepidic) | 81 | 32 (100) | 43 (49.4) | 6 (20.0) | |
Invasive (non-lepidic) | 68 | 0 | 44 (50.6) | 24 (80.0) | |
